Matinas BioPharma Holdings IncNYSE American:MTNB
- LAST PRICE0.6301
- TODAY'S CHANGE (%)0.0502 (8.6567%)
- Bid / Lots0.6300/ 2
- Ask / Lots0.6600/ 10
- Open / Previous Close0.5625 / 0.5799
- Day Range
- 52 Week Range
- Volume111,007
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MTNB |
|---|---|---|
| 09:32 ET | 371 | 0.5625 |
| 09:33 ET | 202 | 0.54051 |
| 10:00 ET | 100 | 0.5675 |
| 10:02 ET | 10600 | 0.5786 |
| 10:04 ET | 900 | 0.575 |
| 10:18 ET | 999 | 0.5443 |
| 10:27 ET | 4472 | 0.5799 |
| 10:33 ET | 1000 | 0.5788 |
| 10:40 ET | 10790 | 0.5426 |
| 10:54 ET | 200 | 0.5698 |
| 11:07 ET | 100 | 0.569701 |
| 11:34 ET | 100 | 0.57 |
| 11:43 ET | 600 | 0.5798 |
| 12:03 ET | 200 | 0.5798 |
| 12:06 ET | 1793 | 0.58 |
| 12:12 ET | 1027 | 0.5798 |
| 12:19 ET | 125 | 0.58 |
| 12:26 ET | 100 | 0.58 |
| 12:37 ET | 325 | 0.59 |
| 12:48 ET | 600 | 0.5937 |
| 12:51 ET | 13004 | 0.581 |
| 12:55 ET | 400 | 0.5938 |
| 12:57 ET | 7210 | 0.6 |
| 01:11 ET | 800 | 0.618 |
| 01:15 ET | 100 | 0.6227 |
| 01:22 ET | 1000 | 0.6327 |
| 01:26 ET | 300 | 0.6403 |
| 01:27 ET | 15162 | 0.6326 |
| 01:29 ET | 200 | 0.6403 |
| 01:33 ET | 284 | 0.6327 |
| 01:36 ET | 17894 | 0.61 |
| 01:38 ET | 1000 | 0.6002 |
| 01:42 ET | 3000 | 0.6403 |
| 01:45 ET | 277 | 0.6404 |
| 01:47 ET | 1400 | 0.630001 |
| 01:49 ET | 3198 | 0.63 |
| 01:54 ET | 200 | 0.64 |
| 02:00 ET | 700 | 0.630199 |
| 02:02 ET | 500 | 0.6498 |
| 02:05 ET | 200 | 0.6499 |
| 02:07 ET | 3929 | 0.66 |
| 02:12 ET | 834 | 0.645 |
| 02:14 ET | 542 | 0.659999 |
| 02:16 ET | 742 | 0.645 |
| 02:23 ET | 434 | 0.6301 |
| 02:25 ET | 100 | 0.63 |
| 02:27 ET | 200 | 0.6301 |
Oct 31, 2024
DJ Matinas BioPharma Cut to Hold From Buy by Maxim Group, from 3:12PM ET on Thursday Oct 31, 2024 by Dow Jones
3:12PM ET on Thursday Oct 31, 2024 by Dow JonesPress Release: Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow JonesMatinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Matinas BioPharma Holdings Inc | 2.9M | -0.1x | --- |
Oncternal Therapeutics Inc | 3.4M | -0.1x | --- |
Aditxt Inc | 2.8M | 0.0x | --- |
Azitra Inc | 3.6M | -0.1x | --- |
Kaleido Biosciences Inc | 4.3K | 0.0x | --- |
Biodexa Pharmaceuticals PLC | 2.6M | 0.0x | --- |
Company Information
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.
Contact Information
- Headquarters
- Suite 302, 1545 Route 206 SouthBEDMINSTER, NJ, United States 07921
- Phone
- 908-443-1860
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Eric Ende
- President, Chief Executive Officer, Director
- Jerome Jabbour
- Chief Financial Officer
- Keith Kucinski
- Chief Technology Officer
- Hui Liu
- Chief Business Officer
- Thomas Hoover
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.1M |
Matinas BioPharma Holdings Inc does not pay a dividend. | |
Beta | 1.66 |
EPS | $-4.56 |
Book Value | $4.43 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
